InsiderSignal.AI

InsiderSignal.ai

SYRE - Spyre Therapeutics, Inc.

Insider Sale by Burrows Scott L (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Burrows Scott L, serving as CFO at Spyre Therapeutics, Inc. (SYRE), sold 7,500 shares at $49.34 per share, for a total transaction value of $370,076.00. Following this transaction, Burrows Scott L now holds 97,994 shares of SYRE.

This sale represents a 7.00% decrease in Burrows Scott L's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 2 days after the trade was made.

Spyre Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Burrows Scott L

CFO

Scott L. Burrows is the Chief Financial Officer of Spyre Therapeutics, Inc. (NASDAQ: SYRE), a biotechnology company focused on developing therapies for immune-mediated diseases, a role he has held since September 1, 2023.[[1]](https://fintool.com/app/research/companies/SYRE/people/scott-burrows)[[6]](https://www.spyre.com/people/scott-burrows) At 48 years old, Burrows brings over two decades of biopharma finance experience, including prior positions as CFO (2021–2023) and VP of Finance (2019–2021) at Arcutis Biotherapeutics, where he led the IPO and financings; Head of International Investor Relations at Shire (2018–2019) during its Takeda acquisition; and 15 years at Amgen in FP&A, treasury, and investor relations.[[1]](https://fintool.com/app/research/companies/SYRE/people/scott-burrows) Burrows holds a B.A. and M.B.A. from UCLA and is a licensed CPA (inactive).[[1]](https://fintool.com/app/research/companies/SYRE/people/scott-burrows) As CFO, he has overseen financial stewardship during Spyre's growth from a market cap under $50 million pre-merger to over $1 billion by end-2023, including signing key earnings releases and managing compensation tied to clinical milestones like SPY001/SPY002 advancements.[[1]](https://fintool.com/app/research/companies/SYRE/people/scott-burrows) Recent insider trades include selling 18,428 shares on September 2, 2025, for tax obligations on RSUs, and 2,500 shares on March 3, 2026, under a Rule 10b5-1 plan after exercising options, retaining 97,994 shares.[[2]](https://www.investing.com/news/insider-trading-news/burrows-spyre-therapeutics-cfo-sells-299k-in-shares-93CH-4223165)[[3]](https://www.stocktitan.net/sec-filings/SYRE/form-4-spyre-therapeutics-inc-insider-trading-activity-6045edd82436.html)[[4]](https://www.marketbeat.com/instant-alerts/scott-burrows-sells-2500-shares-of-spyre-therapeutics-nasdaqsyre-stock-2026-03-03/)

View full insider profile →

Trade Price

$49.34

Quantity

7,500

Total Value

$370,076.00

Shares Owned

97,994

Trade Date

Wednesday, April 1, 2026

3 days ago

SEC Filing Date

Friday, April 3, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Spyre Therapeutics, Inc.

Company Overview

No company information available
View news mentioning SYRE

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5339951

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime